

Xue-Tao Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2685969/publications.pdf>

Version: 2024-02-01

41
papers

1,176
citations

331670

21
h-index

395702

33
g-index

42
all docs

42
docs citations

42
times ranked

1504
citing authors

#	ARTICLE	IF	CITATIONS
1	Folate-modified triptolide liposomes target activated macrophages for safe rheumatoid arthritis therapy. <i>Biomaterials Science</i> , 2022, 10, 499-513.	5.4	14
2	Multifunctional icariin and tanshinone IIA co-delivery liposomes with potential application for Alzheimer's disease. <i>Drug Delivery</i> , 2022, 29, 1648-1662.	5.7	10
3	Multifunctional osthole liposomes and brain targeting functionality with potential applications in a mouse model of Alzheimer's disease. <i>Journal of Liposome Research</i> , 2021, 31, 267-278.	3.3	8
4	Enhanced antitumour efficiency of RGD-modified epirubicin plus tetrandrine liposomes in treatment of gastric cancer via inhibiting tumour metastasis. <i>Journal of Liposome Research</i> , 2021, 31, 145-157.	3.3	5
5	Enhanced antitumour efficacy of functionalized doxorubicin plus schisandrin B co-delivery liposomes via inhibiting epithelial-mesenchymal transition. <i>Journal of Liposome Research</i> , 2021, 31, 113-129.	3.3	7
6	A trace alkaloid, oleraisoindole A from <i>Portulaca oleracea</i> L. and its anticholinesterase effect. <i>Natural Product Research</i> , 2021, 35, 350-353.	1.8	13
7	The anti-ovarian cancer effect of RPV modified paclitaxel plus schisandra B liposomes in SK-OV-3 cells and tumor-bearing mice. <i>Life Sciences</i> , 2021, 285, 120013.	4.3	6
8	Combination of targeted daunorubicin liposomes and targeted emodin liposomes for treatment of invasive breast cancer. <i>Journal of Drug Targeting</i> , 2020, 28, 245-258.	4.4	41
9	Tumor Microenvironmental Responsive Liposomes Simultaneously Encapsulating Biological and Chemotherapeutic Drugs for Enhancing Antitumor Efficacy of NSCLC. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 6451-6468.	6.7	17
10	GGP modified daunorubicin plus dioscin liposomes inhibit breast cancer by suppressing epithelial-mesenchymal transition. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 916-930.	2.0	8
11	Dual variable of drug loaded micelles in both particle and electrical charge on gastric cancer treatment. <i>Journal of Drug Targeting</i> , 2020, 28, 1071-1084.	4.4	9
12	Enhanced antitumor efficacy using epirubicin and schisandrin B co-delivery liposomes modified with PFV via inhibiting tumor metastasis. <i>Drug Development and Industrial Pharmacy</i> , 2020, 46, 621-634.	2.0	5
13	Transferrin-Modified Osthole PEGylated Liposomes Travel the Blood-Brain Barrier and Mitigate Alzheimer's Disease-Related Pathology in APP/PS-1 Mice. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 2841-2858.	6.7	65
14	RPV-modified epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply. <i>Cancer Science</i> , 2020, 111, 621-636.	3.9	24
15	A new alkaloid from <i>Portulaca oleracea</i> L. and its antiacetylcholinesterase activity. <i>Natural Product Research</i> , 2019, 33, 2583-2590.	1.8	29
16	Inhibition of tumor metastasis by targeted daunorubicin and dioscin codelivery liposomes modified with PFV for the treatment of non-small-cell lung cancer. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 4071-4090.	6.7	42
17	Development of RGD modified epirubicin-dihydroartemisinin liposomes for treatment of non-small-cell lung cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2019, 47, 1947-1960.	2.8	37
18	The efficacy of RGD modified liposomes loaded with vinorelbine plus tetrandrine in treating resistant brain glioma. <i>Journal of Liposome Research</i> , 2019, 29, 21-34.	3.3	26

#	ARTICLE	IF	CITATIONS
19	Development of functional docetaxel nanomicelles for treatment of brain glioma. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 1180-1190.	2.8	21
20	Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 616-628.	2.8	42
21	Hyaluronic acid modified daunorubicin plus honokiol cationic liposomes for the treatment of breast cancer along with the elimination vasculogenic mimicry channels. <i>Journal of Drug Targeting</i> , 2018, 26, 793-805.	4.4	32
22	PTD modified paclitaxel anti-resistant liposomes for treatment of drug-resistant non-small cell lung cancer. <i>Journal of Liposome Research</i> , 2018, 28, 236-248.	3.3	11
23	Nanostructured Layered Terbium Hydroxide Containing NASIDs: In Vitro Physicochemical and Biological Evaluations. <i>Journal of Nanoscience and Nanotechnology</i> , 2018, 18, 5320-5326.	0.9	5
24	Vinorelbine cationic liposomes modified with wheat germ agglutinin for inhibiting tumor metastasis in treatment of brain glioma. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 524-537.	2.8	19
25	Functional paclitaxel plus honokiol micelles destroying tumour metastasis in treatment of non-small-cell lung cancer. <i>Artificial Cells, Nanomedicine and Biotechnology</i> , 2018, 46, 1154-1169.	2.8	19
26	The efficacy of WGA modified daunorubicin anti-resistant liposomes in treatment of drug-resistant MCF-7 breast cancer. <i>Journal of Drug Targeting</i> , 2017, 25, 541-553.	4.4	10
27	The anti-sepsis activity of the components of Huanglian Jiedu Decoction with high lipid A-binding affinity. <i>International Immunopharmacology</i> , 2017, 46, 87-96.	3.8	27
28	Antitumor efficacy of Lf modified daunorubicin plus honokiol liposomes in treatment of brain glioma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 106, 185-197.	4.0	28
29	Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG 2000 -transferrin in treatment of brain glioma. <i>European Journal of Pharmaceutical Sciences</i> , 2017, 96, 129-140.	4.0	67
30	Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 7433-7451.	6.7	53
31	Multifunctional targeting vinorelbine plus tetrandrine liposomes for treating brain glioma along with eliminating glioma stem cells. <i>Oncotarget</i> , 2016, 7, 24604-24622.	1.8	27
32	Design and evaluation of an innovative floating and bioadhesive multiparticulate drug delivery system based on hollow structure. <i>International Journal of Pharmaceutics</i> , 2016, 503, 41-55.	5.2	19
33	Effects of Tanshinone IIA on the modulation of miR-33a and the SREBP-2/Pcsk9 signaling pathway in hyperlipidemic rats. <i>Molecular Medicine Reports</i> , 2016, 13, 4627-4635.	2.4	28
34	The antitumor activity of PNA modified vinblastine cationic liposomes on Lewis lung tumor cells: In vitro and in vivo evaluation. <i>International Journal of Pharmaceutics</i> , 2015, 487, 223-233.	5.2	38
35	A Combination of Targeted Sunitinib Liposomes and Targeted Vinorelbine Liposomes for Treating Invasive Breast Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2015, 11, 1568-1582.	1.1	37
36	Targeting Epirubicin Plus Quinacrine Liposomes Modified with DSPE-PEG₂₀₀₀-C(RGDfK) Conjugate for Eliminating Invasive Breast Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2015, 11, 1339-1353.	1.1	19

#	ARTICLE	IF	CITATIONS
37	PEGylated VRB plus quinacrine cationic liposomes for treating non-small cell lung cancer. <i>Journal of Drug Targeting</i> , 2015, 23, 232-243.	4.4	25
38	Multifunctional targeting daunorubicin plus quinacrine liposomes, modified by wheat germ agglutinin and tamoxifen, for treating brain glioma and glioma stem cells. <i>Oncotarget</i> , 2014, 5, 6497-6511.	1.8	51
39	Advances in investigations on the mechanism of cancer multidrug resistance and the liposomes-based treatment strategy. <i>Journal of Pharmaceutical Investigation</i> , 2014, 44, 493-504.	5.3	6
40	Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. <i>Biomaterials</i> , 2014, 35, 5591-5604.	11.4	153
41	Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer. <i>Biomaterials</i> , 2014, 35, 7610-7621.	11.4	73